Immatics (NASDAQ:IMTX) Short Interest Update

Immatics (NASDAQ:IMTX) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 8,910,000 shares, a growth of 6.2% from the March 15th total of 8,390,000 shares. Based on an average daily trading volume, of 526,500 shares, the days-to-cover ratio is currently 16.9 days.

Immatics Price Performance

Shares of NASDAQ IMTX opened at $10.40 on Tuesday. The business has a 50-day moving average of $11.55 and a 200-day moving average of $10.45. The stock has a market capitalization of $880.46 million, a price-to-earnings ratio of -8.00 and a beta of 0.67. Immatics has a fifty-two week low of $6.31 and a fifty-two week high of $13.16.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.09. The firm had revenue of $17.14 million during the quarter, compared to analysts’ expectations of $11.78 million. Immatics had a negative return on equity of 43.58% and a negative net margin of 179.67%. On average, sell-side analysts expect that Immatics will post -1.44 EPS for the current year.

Hedge Funds Weigh In On Immatics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Immatics by 13.3% in the fourth quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock valued at $66,896,000 after acquiring an additional 747,772 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Immatics by 0.9% in the 1st quarter. Nantahala Capital Management LLC now owns 2,944,659 shares of the company’s stock valued at $23,528,000 after purchasing an additional 25,997 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Immatics by 44.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,334,169 shares of the company’s stock valued at $24,579,000 after purchasing an additional 719,634 shares during the last quarter. Vestal Point Capital LP bought a new position in Immatics during the fourth quarter worth about $22,113,000. Finally, Goldman Sachs Group Inc. increased its position in Immatics by 324.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock worth $16,310,000 after buying an additional 1,183,860 shares during the last quarter. 64.41% of the stock is owned by institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.